Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 28, Issue 14, Pages 2231-2242Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/13524585221118676
Keywords
Multiple sclerosis; natalizumab; neurofilament-light; contactin-1; MRI volumetrics
Categories
Funding
- Dutch MS Research Foundation [18-358f]
Ask authors/readers for more resources
This study found that the Year 1 sNfL level can predict long-term brain atrophy in patients treated with natalizumab for RRMS, while the sCNTN1 level did not show a clear predictive value.
Background: Despite highly effective treatment strategies for patients with relapsing-remitting multiple sclerosis (RRMS), long-term neurodegeneration and disease progression are often considerable. Accurate blood-based biomarkers that predict long-term neurodegeneration are lacking. Objective: To assess the predictive value of serum neurofilament-light (sNfL) and serum contactin-1 (sCNTN1) for long-term magnetic resonance imaging (MRI)-derived neurodegeneration in natalizumab-treated patients with RRMS. Methods: sNfL and sCNTN1 were measured in an observational cohort of natalizumab-treated patients with RRMS at baseline (first dose) and at 3 months, Year 1, Year 2, and last follow-up (median = 5.2 years) of treatment. Disability progression was quantified using EDSS-plus criteria. Neurodegeneration was measured by calculating annualized percentage brain, ventricular, and thalamic volume change (PBVC, VVC, and TVC, respectively). Linear regression analysis was performed to identify longitudinal predictors of neurodegeneration. Results: In total, 88 patients (age = 37 +/- 9 years, 75% female) were included, of whom 48% progressed. Year 1 sNfL level (not baseline or 3 months) was associated with PBVC (standardized (std.) beta = -0.26, p = 0.013), VVC (standardized beta = 0.36, p < 0.001), and TVC (standardized beta = -0.24, p = 0.02). For sCNTN1, only 3-month level was associated with VVC (standardized beta = -0.31, p = 0.002). Conclusion: Year 1 (but not baseline) sNfL level was predictive for long-term brain atrophy in patients treated with natalizumab. sCNTN1 level did not show a clear predictive value.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available